Recombinant vaccines against the mononegaviruses-What we have learned from animal disease controls

Virus Research

Volumn 162, Issue 1-2, 2011, Pages 63-71

  Sato, Hiroki ^a   Yoneda, Misako ^a   Honda, Tomoyuki ^a   Kai, Chieko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Animal disease control; Mononegaviruses; Recombinant vaccines

Indexed keywords

COMPLEMENTARY DNA; MARKER VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA RABIES GLYCOPROTEIN RECOMBINANT VACCINE; VACCINIA RPV GLYCOPROTEIN RECOMBINANT VACCINE; VACCINIA VACCINE;

GENE INACTIVATION; INFECTION CONTROL; INFECTION PREVENTION; MOLECULAR CLONING; MONONEGAVIRALES; MONONEGAVIRALES INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRAL GENETICS; VIRUS ATTENUATION; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; CATTLE; CATTLE DISEASES; CROSS PROTECTION; DNA, COMPLEMENTARY; DOG DISEASES; DOGS; LEISHMANIA MAJOR; LEISHMANIASIS; POXVIRIDAE; REVERSE GENETICS; RINDERPEST; RINDERPEST VIRUS; TRANSGENES; VACCINATION; VACCINES, ATTENUATED; VACCINES, COMBINED; VACCINES, SYNTHETIC; VACCINIA;

ANIMALIA; DNA VIRUSES;

EID: 81555228638     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.09.038     Document Type: Review

References (100)

1. Aguilar-Setien A., Leon Y.C., Tesoro E.C., Kretschmer R., Brochier B., et al. Vaccination of vampire bats using recombinant vaccinia-rabies virus. Journal of Wildlife Diseases 2002, 38:539-544.
2. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:17264-17269.
3. Barrett T., Belsham G.J., Subbarao S.M., Evans S.A. Immunization with a vaccinia recombinant expressing the F protein protects rabbits from challenge with a lethal dose of rinderpest virus. Virology 1989, 170:11-18.
4. Bartlett E.J., Cruz A.M., Esker J., Castano A., Schomacker H., et al. Human parainfluenza virus type 1C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. Journal of Virology 2008, 82:8965-8977.
5. Belsham G.J., Anderson E.C., Murray P.K., Anderson J., Barrett T. Immune response and protection of cattle and pigs generated by a vaccinia virus recombinant expressing the F protein of rinderpest virus. Veterinary Record 1989, 124:655-658.
6. Blancou J., Kieny M.P., Lathe R., Lecocq J.P., Pastoret P.P., et al. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 1986, 322:373-375.
7. Blixenkrone-Moller M., Svansson V., Have P., Orvell C., Appel M., et al. Studies on manifestations of canine distemper virus infection in an urban dog population. Veterinary Microbiology 1993, 37:163-173.
8. Boursnell M.E., Green P.F., Samson A.C., Campbell J.I., Deuter A., et al. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology 1990, 178:297-300.
9. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Neglected Tropical Diseases [Electronic Resource] 2007, 1:e96.
10. Brandler S., Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comparative Immunology, Microbiology & Infectious Diseases 2008, 31:271-291.
11. Buonocore L., Blight K.J., Rice C.M., Rose J.K. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. Journal of Virology 2002, 76:6865-6872.
12. Childs K., Stock N., Ross C., Andrejeva J., Hilton L., et al. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 2007, 359:190-200.
13. Clarke D.K., Cooper D., Egan M.A., Hendry R.M., Parks C.L., et al. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Seminars in Immunopathology 2006, 28:239-253.
14. Clarke D.K., Nasar F., Lee M., Johnson J.E., Wright K., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. Journal of Virology 2007, 81:2056-2064.
15. Cliquet F., Aubert M. Elimination of terrestrial rabies in Western European countries. Developments in Biologicals 2004, 119:185-204.
16. Coleman J.R., Papamichail D., Skiena S., Futcher B., Wimmer E., et al. Virus attenuation by genome-scale changes in codon pair bias. Science 2008, 320:1784-1787.
17. del Valle J.R., Devaux P., Hodge G., Wegner N.J., McChesney M.B., et al. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. Journal of Virology 2007, 81:10597-10605.
18. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. Journal of Infectious Diseases 2005, 191:207-214.
19. Dietze R., Barros G.B., Teixeira L., Harris J., Michelson K., et al. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clinical Infectious Diseases 1997, 25:1240-1242.
20. Dubovi E.J., Wagner R.R. Spatial relationships of the proteins of vesicular stomatitis virus: induction of reversible oligomers by cleavable protein cross-linkers and oxidation. Journal of Virology 1977, 22:500-509.
21. Durbin A.P., McAuliffe J.M., Collins P.L., Murphy B.R. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 1999, 261:319-330.
22. Fenner F. Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Research in Virology 1989, 140:465-466. (discussion 487-491).
23. Flanagan E.B., Schoeb T.R., Wertz G.W. Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice. Journal of Virology 2003, 77:5740-5748.
24. Flanagan E.B., Zamparo J.M., Ball L.A., Rodriguez L.L., Wertz G.W. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. Journal of Virology 2001, 75:6107-6114.
25. Giavedoni L., Jones L., Mebus C., Yilma T. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:8011-8015.
26. Gotoh B., Komatsu T., Takeuchi K., Yokoo J. Paramyxovirus strategies for evading the interferon response. Reviews in Medical Virology 2002, 12:337-357.
27. Halfmann P., Kim J.H., Ebihara H., Noda T., Neumann G., et al. Generation of biologically contained Ebola viruses. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:1129-1133.
28. Halfmann P., Ebihara H., Marzi A., Hatta Y., Watanabe S., et al. Replication-deficient ebolavirus as a vaccine candidate. Journal of Virology 2009, 83:3810-3815.
29. Hirama K., Goto Y., Uema M., Endo Y., Miura R., et al. Phylogenetic analysis of the hemagglutinin (H) gene of canine distemper viruses isolated from wild masked palm civets (Paguma larvata). Journal of Veterinary Medical Science 2004, 66:1575-1578.
30. Inui K., Barrett T., Kitching R.P., Yamanouchi K. Long-term immunity in cattle vaccinated with a recombinant rinderpest vaccine. Veterinary Record 1995, 137:669-670.
31. Iwatsuki K., Tokiyoshi S., Hirayama N., Nakamura K., Ohashi K., et al. Antigenic differences in the H proteins of canine distemper viruses. Veterinary Microbiology 2000, 71:281-286.
32. Iwatsuki K., Miyashita N., Yoshida E., Gemma T., Shin Y., et al. Molecular and phylogenetic analysis of the haemagglutinin (H) proteins of field isolates of canine distemper virus from naturally infected dogs. Journal of General Virology 1997, 78:373-380.
33. Jayakar H.R., Whitt M.A. Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. Journal of Virology 2002, 76:8011-8018.
34. Jayakar H.R., Jeetendra E., Whitt M.A. Rhabdovirus assembly and budding. Virus Research 2004, 106:117-132.
35. Kai C., Yoneda M. Henipavirus infections-an expanding zoonosis from fruit bats. Journal of Disaster Research 2011, 6:390-397.
36. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340:174-182.
37. Kasama Y., Satoh M., Saito M., Okada S., Kai C., et al. Evaluation of a recombinant measles virus as the expression vector of hepatitis C virus envelope proteins. World Journal of vaccines 2011, 1:98-103.
38. Kato A., Kiyotani K., Sakai Y., Yoshida T., Nagai Y. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO Journal 1997, 16:578-587.
39. Kato A., Kiyotani K., Kubota T., Yoshida T., Tashiro M., et al. Importance of the anti-interferon capacity of Sendai virus C protein for pathogenicity in mice. Journal of Virology 2007, 81:3264-3271.
40. Kennedy S., Kuiken T., Jepson P.D., Deaville R., Forsyth M., et al. Mass die-off of Caspian seals caused by canine distemper virus. Emerging Infectious Diseases 2000, 6:637-639.
41. Kieny M.P., Lathe R., Drillien R., Spehner D., Skory S., et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984, 312:163-166.
42. Kiyotani K., Sakaguchi T., Kato A., Nagai Y., Yoshida T. Paramyxovirus Sendai virus V protein counteracts innate virus clearance through IRF-3 activation, but not via interferon, in mice. Virology 2007, 359:82-91.
43. Klas S.D., Robison C.S., Whitt M.A., Miller M.A. Adjuvanticity of an IL-12 fusion protein expressed by recombinant deltaG-vesicular stomatitis virus. Cellular Immunology 2002, 218:59-73.
44. Klas S.D., Lavine C.L., Whitt M.A., Miller M.A. IL-12-assisted immunization against Listeria monocytogenes using replication-restricted VSV-based vectors. Vaccine 2006, 24:1451-1461.
45. Krishnamurthy S., Huang Z., Samal S.K. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 2000, 278:168-182.
46. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. Journal of Virology 2000, 74:6564-6569.
47. Liniger M., Zuniga A., Tamin A., Azzouz-Morin T.N., Knuchel M., et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 2008, 26:2164-2174.
48. Mahapatra M., Parida S., Baron M.D., Barrett T. Matrix protein and glycoproteins F and H of Peste-des-petits-ruminants virus function better as a homologous complex. Journal of General Virology 2006, 87:2021-2029.
49. Mamaev L.V., Visser I.K., Belikov S.I., Denikina N.N., Harder T., et al. Canine distemper virus in Lake Baikal seals (Phoca sibirica). Veterinary Record 1996, 138:437-439.
50. Mebatsion T., Verstegen S., De Vaan L.T., Romer-Oberdorfer A., Schrier C.C. A recombinant Newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos. Journal of Virology 2001, 75:420-428.
51. Meulemans G., Letellier C., Gonze M., Carlier M., Burny A. Newcastle disease virus F glycoprotein expressed from a recombinant vaccinia virus vector protects chickens against live-virus challenge. Avian Pathology 1988, 17:821-827.
52. Morell V. Canine distemper virus. Serengeti's big cats going to the dogs. Science 1994, 264:1664.
53. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. Journal of Virology 2006, 80:4447-4457.
54. Ngichabe C.K., Wamwayi H.M., Barrett T., Ndungu E.K., Black D.N., et al. Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle. Epidemiology and Infection 1997, 118:63-70.
55. Ohashi K., Iwatsuki K., Murata K., Miyashita M., Hukumoto Y., et al. Properties of a new CDV isolate from a raccoon dog (Nyctereutes procyonoides viverrinus) in Japan. Veterinary Record 2001, 148:148-150.
56. Osterhaus A.D., Groen J., De Vries P., UytdeHaag F.G., Klingeborn B., et al. Canine distemper virus in seals. Nature 1988, 335:403-404.
57. Parida S., Mahapatra M., Kumar S., Das S.C., Baron M.D., et al. Rescue of a chimeric rinderpest virus with the nucleocapsid protein derived from peste-des-petits-ruminants virus: use as a marker vaccine. Journal of General Virology 2007, 88:2019-2027.
58. Pastoret P.P., Vanderplasschen A. Poxviruses as vaccine vectors. Comparative Immunology, Microbiology and Infectious Diseases 2003, 26:343-355.
59. Perkus M.E., Piccini A., Lipinskas B.R., Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science 1985, 229:981-984.
60. Plowright W., Ferris R.D. Studies with rinderpest virus in tissue culture. III. The stability of cultured virus and its use in virus neutralization tests. Archiv fur die Gesamte Virusforschung 1962, 11:516-553.
61. Poole E., He B., Lamb R.A., Randall R.E., Goodbourn S. The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 2002, 303:33-46.
62. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. Journal of Virology 2005, 79:15043-15053.
63. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. Journal of Virology 1998, 72:4704-4711.
64. Roberts A., Buonocore L., Price R., Forman J., Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. Journal of Virology 1999, 73:3723-3732.
65. Roberts A., Reuter J.D., Wilson J.H., Baldwin S., Rose J.K. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. Journal of Virology 2004, 78:3196-3199.
66. Roelke-Parker M., Munson L., Packer C., Kock R., Cleaveland S., et al. A canine distemper virus epidemic in Serengeti lions (Panthera leo). Nature 1996, 379:441-445.
67. Romero C.H., Barrett T., Chamberlain R.W., Kitching R.P., Fleming M., et al. Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses. Virology 1994, 204:425-429.
68. Romero C.H., Barrett T., Kitching R.P., Carn V.M., Black D.N. Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus. Veterinary Record 1994, 135:152-154.
69. Romero C.H., Barrett T., Evans S.A., Kitching R.P., Gershon P.D., et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease. Vaccine 1993, 11:737-742.
70. Rupprecht C.E., Hanlon C.A., Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Developments in Biologicals 2004, 119:173-184.
71. Rupprecht C.E., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:7947-7950.
72. Satoh M., Saito M., Tanaka K., Iwanaga S., Ali S.N., et al. Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse. Comparative Immunology, Microbiology and Infectious Diseases 2010, 33:e81-e88.
73. Schaap-Nutt A., D'Angelo C., Scull M.A., Amaro-Carambot E., Nishio M., et al. Human parainfluenza virus type 2V protein inhibits interferon production and signaling and is required for replication in non-human primates. Virology 2010, 397:285-298.
74. Schnell M.J., Buonocore L., Boritz E., Ghosh H.P., Chernish R., et al. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO Journal 1998, 17:1289-1296.
75. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO Journal 1994, 13:4195-4203.
76. Singh M., Cattaneo R., Billeter M.A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. Journal of Virology 1999, 73:4823-4828.
77. Smith G.L., Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 1983, 25:21-28.
78. Tabira T., Hara H. Vaccination--update. Rinsho Shinkeigaku 2006, 46:927.
79. Takao S.I., Kiyotani K., Sakaguchi T., Fujii Y., Seno M., et al. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses. Journal of Virology 1997, 71:832-838.
80. Takayama I., Kubo M., Takenaka A., Fujita K., Sugiyama T., et al. Pathological and phylogenetic features of prevalent canine distemper viruses in wild masked palm civets in Japan. Comparative Immunology, Microbiology & Infectious Diseases 2009, 32:539-549.
81. Tangy F., Naim H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunology 2005, 18:317-326.
82. Tsukiyama K., Yoshikawa Y., Kamata H., Imaoka K., Asano K., et al. Development of heat-stable recombinant rinderpest vaccine. Archive of Virology 1989, 107:225-235.
83. Vanloubbeeck Y., Jones D.E. The immunology of Leishmania infection and the implications for vaccine development. Annals of the New York Academy of Sciences 2004, 1026:267-272.
84. Verardi P.H., Aziz F.H., Ahmad S., Jones L.A., Beyene B., et al. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. Journal of Virology 2002, 76:484-491.
85. Walsh E.P., Baron M.D., Anderson J., Barrett T. Development of a genetically marked recombinant rinderpest vaccine expressing green fluorescent protein. Journal of General Virology 2000, 81:709-718.
86. Walsh E.P., Baron M.D., Rennie L.F., Monaghan P., Anderson J., et al. Recombinant rinderpest vaccines expressing membrane-anchored proteins as genetic markers: evidence of exclusion of marker protein from the virus envelope. Journal of Virology 2000, 74:10165-10175.
87. Wang X.J., Wang O.H., Ge J.Y., Hu S., Bu Z.G. Generation of recombinant vaccinia virus expressing attachment glycoprotein of Nipah virus. Wei Sheng Wu Hsueh Pao-Acta Microbiologica Sinica 2006, 46:644-648.
88. Welter J., Taylor J., Tartaglia J., Paoletti E., Stephensen C.B. Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection. Vaccine 1999, 17:308-318.
89. Welter J., Taylor J., Tartaglia J., Paoletti E., Stephensen C.B. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. Journal of Virology 2000, 74:6358-6367.
90. Wertz G.W., Perepelitsa V.P., Ball L.A. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:3501-3506.
91. Wiktor T.J., Macfarlan R.I., Reagan K.J., Dietzschold B., Curtis P.J., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:7194-7198.
92. Wild T.F., Bernard A., Spehner D., Villeval D., Drillien R. Vaccination of mice against canine distemper virus-induced encephalitis with vaccinia virus recombinants encoding measles or canine distemper virus antigens. Vaccine 1993, 11:438-444.
93. Yamanouchi K., Inui K., Sugimoto M., Asano K., Nishimaki F., et al. Immunisation of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus. Veterinary Record 1993, 132:152-156.
94. Yilma T., Hsu D., Jones L., Owens S., Grubman M., et al. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 1988, 242:1058-1061.
95. Yoneda M., Bandyopadhyay S.K., Shiotani M., Fujita K., Nuntaprasert A., et al. Rinderpest virus H protein: role in determining host range in rabbits. Journal of General Virology 2002, 83:1457-1463.
96. Yoneda M., Guillaume V., Ikeda F., Sakuma Y., Sato H., et al. Establishment of a Nipah virus rescue system. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:16508-16513.
97. Yoneda M., Guillaume V., Sato H., Fujita K., Georges-Courbot M.C., et al. The nonstructural proteins of Nipah virus play a key role in pathogenicity in experimentally infected animals. PLoS ONE [Electronic Resource] 2010, 5:e12709.
98. Yoneda M., Miura R., Barrett T., Tsukiyama-Kohara K., Kai C. Rinderpest virus phosphoprotein gene is a major determinant of species-specific pathogenicity. Journal of Virology 2004, 78:6676-6681.
99. Yoshizaki M., Hironaka T., Iwasaki H., Ban H., Tokusumi Y., et al. Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. Journal of Gene Medicine 2006, 8:1151-1159.
100. Zuniga A., Wang Z., Liniger M., Hangartner L., Caballero M., et al. Attenuated measles virus as a vaccine vector. Vaccine 2007, 25:2974-2983.